For patients with advanced pancreatic cancer who have already received chemotherapy, daraxonrasib extends the time until half of the patients die by twice as long as standard chemotherapy.
Not yet evaluated
No evidence has been gathered for this claim yet.
Not medical advice. For informational purposes only. Always consult a healthcare professional.
For patients with advanced pancreatic cancer who have already received chemotherapy, daraxonrasib extends the time until half of the patients die by twice as long as standard chemotherapy.
See the technical phrasing
In patients with metastatic pancreatic cancer previously treated with chemotherapy, daraxonrasib doubles median overall survival compared to standard chemotherapy.
Score breakdown, mechanism chain, raw evidence, ideal studies needed